Article: [Distribution and infectious characteristics of re-positive cases infected with SARS-CoV-2].
Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
2021 Volume 42, Issue 10, Page(s) 1750–1756
Abstract: ... infected with SARS-CoV-2 were reviewed, and the characteristics and infectivity of the re-positive cases ... immunosuppressive agents. In conclusion, the infectivity of re-positive cases infected with SARS-CoV-2 is generally very ... low. Rare re-positive cases infected with SARS-CoV-2 might cause further transmission. The management ...
| Abstract | Domestic and foreign literatures related to the persistence of SARS-CoV-2 and the re-positive cases infected with SARS-CoV-2 were reviewed, and the characteristics and infectivity of the re-positive cases were analyzed to provide scientific evidence for the improvement of case management and the development of measures to stop the spread of SARS-CoV-2. Existing studies have shown that re-positive rate of SARS-CoV-2 ranged from 2.4% to 19.8%, the median of interval between re-positive detection and discharge was 4-15 days. Following the second course of the disease, the anti-SARS-CoV-2 IgM, IgG and IgA positive rates of the cases were 11.11%-86.08%, 52.00%-100.00% and 61.54%-100.00% respectively, the total antibody and neutralizing antibody positive rates were 98.72% and 88.46%. The viral load of the re-positive cases was lower than that in the initial infection. At least 3 380 re-positive cases have been reported globally. SARS-CoV-2 strains were isolated from the samples of 3 re-positive cases (1 immunodeficiency case and 2 cases with abnormal pulmonary imaging). There were close contacts that were infected by an asymptomatic case taking immunosuppressive agents. In conclusion, the infectivity of re-positive cases infected with SARS-CoV-2 is generally very low. Rare re-positive cases infected with SARS-CoV-2 might cause further transmission. The management approach for the re-positive cases can be based on the assessment of the individual transmission risk according to the pathogen detection results. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19 ; Humans ; Immunoglobulin M ; SARS-CoV-2 | |||||
| Chemical Substances | Antibodies, Neutralizing ; Antibodies, Viral ; Immunoglobulin M | |||||
| Language | Chinese | |||||
| Publishing date | 2021-08-17 | |||||
| Publishing country | China | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 645026-x | |||||
| ISSN | 0254-6450 | |||||
| ISSN | 0254-6450 | |||||
| DOI | 10.3760/cma.j.cn112338-20210506-00367 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.B 3276: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.